Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Serum Hcy, IL-6, and TNF-α were higher, while 25(OH)D3 was lower in the sarcopenia group.

Source: Anthropometric measures. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Scoping review.

Scoping review

Maps the extent and characteristics of research on a topic.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Assessment of screening tools for diabetic sarcopenia in type 2 diabetes mellitus: evidence from a scoping review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Assessment of screening tools for diabetic sarcopenia in type 2 diabetes mellitus: evidence from a scoping review

Scoping review · Frontiers in Endocrinology · 2026

Original publication title

Assessment of screening tools for diabetic sarcopenia in type 2 diabetes mellitus: evidence from a scoping review

Jiawei Yin; Xiaotu Zhang; Jing Cai; Hongshi Zhang; Xuefeng Sun; Zilin Wang; Ye Zhang; Lin Li

Copyright © 2026 Yin, Zhang, Cai, Zhang, Sun, Wang, Zhang and Li.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Various screening approaches for diabetic sarcopenia have been explored, but no single tool is universally validated for T2DM. Combining functional questionnaires with objective assessments like ultrasound or biomarkers may offer a more practical solution. Future research should focus on standardizing thresholds and testing tools in diverse populations.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This study aimed to map and synthesize the available evidence on screening tools for diabetic sarcopenia in patients with type 2 diabetes mellitus (T2DM), highlighting their characteristics, application contexts, and research gaps.

Source: Objective

Abstract: What methods does the paper describe?

A comprehensive search was conducted in PubMed, Web of Science, CNKI, and Wanfang Data to identify studies published from 2010 to Deccember 2025. Studies involving adults with T2DM that evaluated screening tools for sarcopenia against established diagnostic criteria (EWGSOP, AWGS, FNIH, or IWGS) were eligible. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the QUADAS-2 tool. Findings were charted and synthesized narratively, with screening tools grouped into functional assessments, anthropometric measures, biomarker-based methods, imaging approaches, and predictive models.

Source: Methods

Abstract: Results

A total of 24 studies with 9,469 participants were included. The most common screening tools were functional assessments, anthropometric measures, biomarkers, and muscle ultrasound. SARC-F showed moderate sensitivity (13.33%-62.63%) and high specificity (67.30%-91.67%), while SARC-CalF improved diagnostic performance. Muscle ultrasound demonstrated high accuracy, with sensitivity ranging from 71.05% to 95.00%. Predictive models with multiple variables (Age, BMI, HbA1c) showed AUC values between 0.800 and 0.932. Challenges included inconsistent cut-off values and limited validation across diverse populations.

Source: Results

Abstract: Conclusion

Various screening approaches for diabetic sarcopenia have been explored, but no single tool is universally validated for T2DM. Combining functional questionnaires with objective assessments like ultrasound or biomarkers may offer a more practical solution. Future research should focus on standardizing thresholds and testing tools in diverse populations.

Source: Conclusion
Authors’ abstract

Objective

This study aimed to map and synthesize the available evidence on screening tools for diabetic sarcopenia in patients with type 2 diabetes mellitus (T2DM), highlighting their characteristics, application contexts, and research gaps.

Methods

A comprehensive search was conducted in PubMed, Web of Science, CNKI, and Wanfang Data to identify studies published from 2010 to Deccember 2025. Studies involving adults with T2DM that evaluated screening tools for sarcopenia against established diagnostic criteria (EWGSOP, AWGS, FNIH, or IWGS) were eligible. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the QUADAS-2 tool. Findings were charted and synthesized narratively, with screening tools grouped into functional assessments, anthropometric measures, biomarker-based methods, imaging approaches, and predictive models.

Results

A total of 24 studies with 9,469 participants were included. The most common screening tools were functional assessments, anthropometric measures, biomarkers, and muscle ultrasound. SARC-F showed moderate sensitivity (13.33%-62.63%) and high specificity (67.30%-91.67%), while SARC-CalF improved diagnostic performance. Muscle ultrasound demonstrated high accuracy, with sensitivity ranging from 71.05% to 95.00%. Predictive models with multiple variables (Age, BMI, HbA1c) showed AUC values between 0.800 and 0.932. Challenges included inconsistent cut-off values and limited validation across diverse populations.

Conclusion

Various screening approaches for diabetic sarcopenia have been explored, but no single tool is universally validated for T2DM. Combining functional questionnaires with objective assessments like ultrasound or biomarkers may offer a more practical solution. Future research should focus on standardizing thresholds and testing tools in diverse populations.

Publication and source details

Original title: Assessment of screening tools for diabetic sarcopenia in type 2 diabetes mellitus: evidence from a scoping review

Jiawei Yin; Xiaotu Zhang; Jing Cai; Hongshi Zhang; Xuefeng Sun; Zilin Wang; Ye Zhang; Lin Li

Frontiers in Endocrinology · 2026

* Correspondence: Lin Li, 187375569@qq.comCopyright © 2026 Yin, Zhang, Cai, Zhang, Sun, Wang, Zhang and Li.2026Yin, Zhang, Cai, Zhang, Sun, Wang, Zhang and Lihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:27:46.698848+00:00

DOI: 10.3389/fendo.2025.1702479 · PMC12864131